Data Reveals JAK Inhibitor Traction for RA

Oct 25, 2018
By Pharmaceutical Executive Editors

Therapy Watch released data—which uses real-time patient record form data to monitor healthcare market dynamics—proposing that JAK inhibitors have made a strong impression on the Rheumatoid Arthritis (RA) market across France, Germany, Italy, Spain, and the UK (the EU5).

According to the study, JAK inhibitors have expanded their market share across the EU5 from 3.1% in Q3 2017 to 15.6% in Q2 2018. 

native1_300x100
lorem ipsum